Lyophilized Kit for Radiometal-Labeled GRP Conjugates

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing radiopharmaceutical kits for preparing radiometal labeled chelate-functionalized targeting conjugates face issues with long-term stability during storage, flexibility in using different generators, and decomposition due to radiolysis, particularly for GRP receptor targeting conjugates, failing to meet regulatory requirements for lyophilization and stability at room temperature.

Innovation Solution

A lyophilized kit formulation containing non-reducing sugars like trehalose and sucrose, along with radio stabilizers such as ascorbic acid, is developed to stabilize the radiometal labeled chelate-functionalized targeting conjugates, ensuring high purity and stability for at least one year at room temperature, suitable for various generators, and meeting regulatory standards for lyophilization.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If conventional kit formulations are used for radiometal labeling, then the preparation process is simple, but the long-term stability during storage at room temperature is insufficient

Engineering Contradiction:
Improvelong-term stability during storageVSAvoiddecomposition due to radiolysis
Core Design Contradiction:
Stability of the object's compositionVSReliability

Solution Approach 1:

Ascorbic acid is introduced as a radiostabilizer intermediary that protects the radiometal-labeled chelate-functionalized targeting conjugate from radiolysis during storage. The ascorbic acid acts as a sacrificial antioxidant that absorbs radiation-induced oxidative stress, thereby preserving the stability and purity of the radiopharmaceutical composition over extended storage periods at room temperature.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The formulation parameters are optimized by adjusting the concentration of ascorbic acid (typically 0.1-10 mg/mL) and selecting specific chelating agents with appropriate stability constants for the radiometal. These parameter changes enable the composition to maintain >90% radiochemical purity after storage for at least one year at room temperature, resolving the stability-reliability contradiction.

Inventive Principle:
Principle #35Parameter changes

2Adaptability or versatility

If generator-derived radiometal solutions are used, then the preparation is convenient, but flexibility in using various generators with different elution methods is limited

Engineering Contradiction:
Improveflexibility in using various generatorsVSAvoidpreparation convenience
Core Design Contradiction:
Adaptability or versatilityVSEase of operation

Solution Approach 1:

The kit formulation is designed with universal compatibility for radiometals from different generator types (e.g., 68Ga from 68Ge/68Ga generators, 177Lu from 177Yb/177Lu generators). The formulation accommodates varying elution conditions (HCl concentrations, volumes, and flow rates) by using robust chelating agents and buffers that maintain effective radiometal complexation across different generator protocols, thereby achieving both versatility and operational convenience.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Duration of action of stationary object

If lyophilization is applied to improve storage stability, then the shelf life is extended, but the cake appearance and dose uniformity may not meet regulatory requirements

Engineering Contradiction:
Improveshelf lifeVSAvoiddose uniformity and cake appearance
Core Design Contradiction:
Duration of action of stationary objectVSManufacturing precision

Solution Approach 1:

The lyophilized formulation employs a composite matrix consisting of the radiopharmaceutical composition combined with excipients such as sugars (sucrose, trehalose) or amino acids. This composite structure provides structural support during freeze-drying, ensuring uniform cake appearance and homogeneous distribution of the radiometal-labeled compound, thereby meeting regulatory requirements for dose uniformity and visual inspection while achieving extended shelf life.

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation provides radiometal labeled chelate-functionalized targeting conjugates with high purity (>90%) and stability, allowing easy preparation and storage at room temperature for up to a year, meeting regulatory requirements for dose uniformity and cake appearance.

Implementation Method 1

The present invention is directed towards a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized targeting conjugates

Methodology Applied
Scientific EffectLyophilization: Freeze Drying

Implementation Method 2

Provides the radiometal labeled chelate-functionalized targeting conjugate without or minor decomposition by radiolysis

Methodology Applied
Scientific EffectRadiolysis prevention: Radiation

Data Source

PatentUS20250319214A1A novel kit for radiopharmaceutical preparation of a radiometal labeled chelate-functionalized targeting conjugate
Publication Date: 2025.10.16 LANTHEUS BIOSCIENCES LTD

AI summary

Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprisinga chelate-functionalized GRP receptor targeting conjugate comprisingi. a chelating moietyii. at least one targeting moiety, wherein said targeting moiety is a GRP receptor (GRPr) targeting peptide, andiii. optionally, at least one linker, connecting the chelating moiety with the GRP receptor (GRPr) targeting moiety, andat least one GRP receptor (GRPr) targeting moiety,at least one non-reducing sugar selected from the group comprising trehalose and sucrose, andat least one radio stabilizer, selected from the group comprising ascorbic acid, ascorbic acid salts, gentisic acid, gentisic acid salts, or mixtures thereof.